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The molecular architecture of the mature N-glycome
is dynamic, with consequences for both normal and
pathologic processes. Elucidating cellular mecha-
nisms that modulate the N-linked glycome is, there-
fore, crucial. The unfolded protein response (UPR)
is classically responsible for maintaining proteosta-
sis in the secretory pathway by defining levels of
chaperones and quality control proteins. Here, we
employ chemical biology methods for UPR regula-
tion to show that stress-independent activation of
the UPR’s XBP1s transcription factor also induces
a panel of N-glycan maturation-related enzymes.
The downstream consequence is a distinctive shift
toward specific hybrid and complex N-glycans on
N-glycoproteins produced from XBP1s-activated
cells, which we characterize by mass spectrometry.
Pulse-chase studies attribute this shift specifically
to altered N-glycan processing, rather than to
changes in degradation or secretion rates. Our find-
ings implicate XBP1s in a new role for N-glycoprotein
biosynthesis, unveiling an important link between
intracellular stress responses and the molecular ar-
chitecture of extracellular N-glycoproteins.
INTRODUCTION
The endoplasmic reticulum (ER) is a specialized protein-folding
factory responsible for producing about one-third of the prote-
ome (Braakman and Bulleid, 2011). The vast majority of proteins
traversing the ER are co- or post-translationally N-glycosylated
by oligosaccharyl transferase (OST) (Aebi, 2013; Zielinska
et al., 2010). A 14-residue oligosaccharide with the structure
Glc3Man9GlcNAc2 is transferred by OST from the lipid-linked
precursor Glc3Man9GlcNAc2-pyrophosphate-dolichol to the
amide nitrogen of Asn side chains in Asn-Xaa-Ser/Thr sequons
(where Xaa s Pro). This immature N-linked glycan is later pro-
cessed and modified in both the ER and the Golgi to ultimately
yield the vast array of distinct molecular structures observed
on mature ER clients (Moremen et al., 2012).
Protein N-glycosylation has important implications for
numerous normal and pathologic processes (Dennis et al.,Chemistry & Biology 22, 1301–12009), including protein folding and stability (Chen et al., 2010;
Culyba et al., 2011), function (Venetz et al., 2015), trafficking (Wu-
jek et al., 2004), quality control (Ruiz-Canada et al., 2009), and
aggregation (Ioannou et al., 1998), as well as auto-immunity
and tumormetastasis (Chui et al., 2001; Ha¨uselmann andBorsig,
2014). Furthermore, although the architecture of the highly
diverse, mature N-linked glycome is known to be dynamic,
responding to environmental conditions and other stimuli
(Hassinen et al., 2011; Lau et al., 2007), the upstream cellular
mechanisms that regulate the composition of the N-glycome
remain poorly delineated (Voss et al., 2014). Elucidating those
mechanisms is important not just for understanding normal
and disease physiology, but also for optimizing the production
of recombinant proteins displaying desirable N-glycoform popu-
lations (Elliott et al., 2003).
The composition of the secretory pathway’s proteostasis
network, which is responsible for the folding and quality control
of secreted, transmembrane, and lysosomal proteins, including
all N-glycoproteins, is regulated by the unfolded protein res-
ponse (UPR) (Ron andWalter, 2007). The UPR typically activates
in response to ER stress caused by the accumulation of unfolded
and misfolded proteins. Aside from transient inhibition of new
protein synthesis, the crucial consequence of this stress-
responsive UPR activation is a large-scale remodeling of the
ER proteostasis network via transcriptional upregulation of
chaperones, folding enzymes, and quality control factors. These
transcriptional responses are propagated by two UPR-specific
transcription factors, X-box binding protein 1-spliced (XBP1s)
and activating transcription factor 6 (ATF6), aswell as a third tran-
scription factor, activating transcription factor 4, which can also
be induced by independent stress response pathways (Schro¨der
and Kaufman, 2005). UPR-mediated upregulation of chaperones
and quality control mechanisms can restore ER proteostasis in
response to a variety of protein misfolding-inducing stressors.
A classic method to activate the UPR and thereby study its
function is the inhibition of ER client protein N-glycosylation by
treatment with tunicamycin (Tm), which prevents the synthesis
of the dolichol-linked N-glycan precursor (Lehle and Tanner,
1976), highlighting the importance of N-glycosylation for ER
proteostasis. The absence of N-linked glycans on nascent ER
clients prevents access to the key ER lectin-based chaperones
calnexin and calreticulin, restricts monitoring by the lectin-based
quality-control machinery, and can also intrinsically destabilize
ER clients (Hammond et al., 1994).
Thus, the paradigmatic role of the UPR is to upregulate chap-
erones and quality-control mechanisms in response to protein312, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1301
misfolding stress. Because N-glycosylation sequons are nor-
mally only partially occupied (Zielinska et al., 2010), it is reason-
able to also expect that UPR activationmight enhance the extent
of ER client protein N-glycosylation (Hammond et al., 1994;
Spear andNg, 2005; Thibault et al., 2011). Such an enhancement
would specifically increase access to lectin-based proteostasis
mechanisms. Consistent with this concept, ER stress can upre-
gulate hexosamine biosynthesis to promote ER client clearance
and prolong life in the face of chronic protein misfolding stress
(Denzel et al., 2014; Wang et al., 2014).
We speculated that the UPR might regulate not just the extent
of protein N-glycosylation, but also the molecular structure of
mature N-glycans. Mature N-glycan architectures are substan-
tially altered in many malignancies (Fry et al., 2011; Ha¨uselmann
and Borsig, 2014; Stowell et al., 2015), yet the mechanisms that
regulate thesealteredN-glycosylationpatterns remain ill-defined.
Concomitantly, it is intriguing to note that a number of malig-
nancies appear to rely on the activation of pro-survival pathways
within the UPR, including constitutive activation of the XBP1s
transcription factor (Bagratuni et al., 2010; Carrasco et al., 2007;
Fujimoto et al., 2003). These observations, in addition to the over-
arching role of the UPR in regulating ER client protein folding and
trafficking, suggested to us that there may be a connection be-
tween UPR activity and N-glycan maturation patterns.
Testing our hypothesis requires studying the biosynthesis of
N-glycoproteins in the presence or absence of UPR-mediated
remodeling of the ER proteostasis network. Unfortunately, ER
stress-inducing small molecules such as Tm, thapsigargin, or
DTT activate the UPR by creating non-physiologic levels of pro-
tein misfolding stress and are highly cytotoxic. These undesired
side effects convolute efforts to study the roles of UPR activation
and the resultant ER proteostasis network remodeling in protein
maturation.
To overcome this challenge, small molecule-regulated
methods for the orthogonal, stress-independent activation of
the key adaptive UPR transcription factors XBP1s and ATF6 in
human cells have been pioneered (Lee et al., 2003; Shoulders
et al., 2013b). Specifically, the ATF6 transcription factor can be
regulated by fusion to a dihydrofolate reductase (DHFR) destabi-
lized domain that is stabilized by administration of trimethoprim
(TMP) (Iwamoto et al., 2010; Shoulders et al., 2013a), while
XBP1s can be placed under control of the tetracycline repressor
and activated by doxycycline (Dox). In cells carrying these chem-
ical genetic tools, such as the HEK293DAX cell line (Shoulders
et al., 2013b), the functional consequences of physiologically
relevant, UPR transcription factor-mediated remodeling of the
ER proteostasis network can be studied in the absence of toxic
protein misfolding stress created by molecules such as Tm,
thapsigargin, or DTT.
Here, we employ stress-independent UPR activation to eluci-
date whether and how UPR-mediated remodeling of the ER pro-
teostasis network regulates N-glycan maturation. We demon-
strate that the XBP1s transcription factor is responsible for
modulating N-glycanmaturation onmodel secreted proteins, re-
sulting in enhanced synthesis of both hybrid and complex N-gly-
cans. Our observations indicate that the IRE1-XBP1s axis of the
UPR can modify N-glycan maturation, unveiling a previously un-
known link between intracellular proteostasis mechanisms and
the molecular architecture of extracellular N-glycoproteins.1302 Chemistry & Biology 22, 1301–1312, October 22, 2015 ª2015 ERESULTS
Transcriptional Regulation of N-Glycan Biosynthesis
and Maturation Pathways by the Unfolded Protein
Response
Affymetrix whole-genome arrays were previously used to eval-
uate the transcriptome of HEK293DAX cells upon small-mole-
cule-mediated activation of XBP1s and/or ATF6 (Shoulders
et al., 2013b). It was observed that these transcription factors
control the levels of partially overlapping sets of ER chaperoning
and quality control mechanisms. Interestingly, gene ontology
enrichment analysis shows that five of the top 24 and two of
the top ten gene sets induced by XBP1s are related to N-glyco-
sylation of ER clients (Shoulders et al., 2013b). Of particular
note, numerous components of the N-glycoprotein biosynthesis
machinery are upregulated by XBP1s or the combination of
XBP1s and ATF6 activation (see Table S1 for quantitative data),
including components of the oligosaccharyltransferase complex
and enzymes involved in the synthesis of the dolichol-linked pre-
cursor to N-glycosylation (Figure 1A, regular italic typeface).
Considering the essential roles of N-glycans in providing ac-
cess to the ER proteostasis network (Hammond et al., 1994),
it is not surprising that enzymes involved in the extent to which
ER clients are N-glycosylated are upregulated by the UPR
transcription factors. Intriguingly, we also observe numerous en-
zymes likely involved inN-glycanmaturation that are upregulated
by XBP1s activation or the combination of both XBP1s and ATF6
activation (Figure 1A, bold italic typeface) (Shoulders et al.,
2013b). The possible connection to ER proteostasis is arguably
less apparent for these enzymes than for those involved in initial
N-glycoprotein biosynthesis. However, the UPR plays a critical
role not just in protein folding, but also in ER client trafficking
and propagating intracellular stress signals to the extracellular
milieu (Taylor and Dillin, 2013). Therefore, motivated by these
transcript-level results, we proceeded to explore the possible
functional consequences of XBP1s and/or ATF6 activation for
the maturation of N-glycans installed on ER client proteins.
XBP1s Modulates N-Glycan Maturation on a Secreted
N-Glycoprotein
Weelected toemploy theCD2adhesiondomain, awell-character-
ized ER client protein (Culyba et al., 2011), in our initial studies.
The Rattus norvegicus CD2 variant employed, henceforth termed
CD2, has the sequence K61I62F63A64N65G66T67 at its single
N-glycosylation sequon, an N-terminal preprotrypsin signal seq-
uence, a hexahistidine tag for purification, and a FLAG tag for
immunoblotting and immunoisolation (Figure 1B) (Murray et al.,
2015). CD2 secreted from HEK293 cells displays two distinctive
N-linked glycoform populations that are readily separated by
SDS-PAGEanalysis (Figure 1C).Weconfirmed that the two bands
observed by immunoblotting of secreted CD2 (N-glycoforms A
indicated by the black arrowhead and N-glycoforms B by
the gray arrowhead in Figure 1C) separate based on their distinc-
tive N-glycan states by showing that peptide-N-glycosidase F
(PNGase F) digestion collapses both bands into a single, lower
molecular weight, non-glycosylated band indicated by the white
arrowhead.
To investigate the influence of XBP1s- and/or ATF6-mediated
remodeling of the ER proteostasis network on CD2 N-glycanlsevier Ltd All rights reserved
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Figure 1. XBP1s Modulates the Molecular Architecture of CD2’s N-Linked Glycan
(A) Gene ontology enrichment analysis identifies numerous genes involved in N-glycoprotein biosynthesis (regular italic typeface) and potentially in N-glycan
maturation (bold italic typeface) that are upregulated primarily by XBP1s (light-gray circle). In addition, a subset of N-glycosylation-related genes is induced
primarily by ATF6 (dark-gray circle) or only when both XBP1s and ATF6 are activated (white circle). MGAT1 upregulation was identified by qPCR.
(B) The CD2 expression construct includes the preprotrypsin leader sequence (PPTLS), a 6x-His tag, a FLAG tag, and the single N-glycosylation sequon shown.
(C) Immunoblot of media harvested from HEK293 cells expressing CD2 displays two distinct bands; N-glycoforms A (black arrowhead) and N-glycoforms B (gray
arrowhead). PNGase F digestion collapses both bands to a single lower molecular weight band (white arrowhead).
(D) Representative immunoblot of lysates from HEK293DAX-CD2 cells after 72 hr of XBP1s and/or ATF6 activation (Dox at 1 mg/ml and/or TMP at 10 mM). A single
N-glycosylated band and a faint non-N-glycosylated band are observed. Probing for known UPR-upregulated proteins confirms transcription factor activation.
(E) Representative immunoblot of CD2 in media corresponding to the lysate samples in (D). Control media is from parent HEK293DAX cells.
(F) Quantification of the data in (E). Error bars represent SEM from biological replicates (n = 3). **p < 0.005, ***p < 0.0005.
(G) Immunoblot showing PNGase F digestion of CD2 secreted fromHEK293DAX-CD2 cells. N-Glycoforms A and B are indicated by the black and gray arrowheads,
respectively, while the white arrowhead indicates the PNGase F-digested, non-N-glycosylated band.
See also Table S1 and Figure S1.maturation, we used CD2-encoding lentivirus to generate stable,
clonal HEK293DAX cells constitutively expressing modest levels
of CD2, which we termed HEK293DAX-CD2 cells. The cells were
treated with vehicle, 1 mg/ml Dox to activate XBP1s, 10 mM
TMP to activate ATF6, or both Dox and TMP to activate both
transcription factors. We confirmed successful activation of
XBP1s and/or ATF6 by analysis of chaperones known to be
induced by these transcription factors (Figure 1D) (Shoulders
et al., 2013b), and ensured that global UPR activation does not
occur upon Dox or TMP treatment by using qPCR to compare
the effects of administering the ER stress-inducing small mole-
cule thapsigargin (Figure S1A).
We next analyzed CD2 N-glycosylation in both the media and
lysate samples by immunoblotting. In cell lysates, we observeChemistry & Biology 22, 1301–1a single high molecular weight N-glycosylated CD2 band and
a low-intensity non-N-glycosylated CD2 band. Activation of
XBP1s and/or ATF6 has no apparent impact on the intracellular
quantity of CD2 or the extent of N-glycosylation (Figure 1D).
Intriguingly, XBP1s and/or ATF6 activation do have distinctive
impacts on secreted CD2 (Figure 1E). CD2 secreted from un-
treated cells displays the expected two N-glycoform bands in
a nearly 1:1 ratio. A reduced quantity of CD2 is secreted upon
ATF6 activation, but the ratio of N-glycoforms remains un-
changed. The quantity of CD2 secreted upon XBP1s activation
is similar to that in untreated cells. Most interestingly, upon
XBP1s activation we observe a nearly complete shift of the
CD2 N-glycoform population from N-glycoforms B (gray arrow-
head) to N-glycoforms A (black arrowhead). Also intriguing, we312, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1303
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Figure 2. XBP1s Activation Does Not Significantly Influence CD2
Secretion or Degradation
(A) Representative auto-radiograms of 35S-labeled CD2 immunoisolated from
HEK293DAX-CD2 media and lysates following a 24-hr pre-activation of XBP1s
(Dox; 1 mg/ml) or no treatment. The metabolic labeling protocol employed is
shown. Control media and lysate were harvested from parent HEK293DAX
cells. Lactacystin (LC) inhibits proteasomal degradation of CD2. Two N-gly-
coforms bands A and B are observed in the media, as indicated by the
arrowheads.
(B–D) Quantification of auto-radiograms in (A). Percentage of CD2 remaining
(B) was calculated by normalizing the secreted and lysate CD2 signal at the
stated times to the total amount of labeled CD2 observed at time = 0 hr.
Percentage of CD2 secreted (C) was calculated by normalizing the secreted
CD2 signal to the total amount of CD2 present at time = 0 hr. The N-glycoforms
ratio A/B (D) was calculated as in Figure 1F. Error bars represent SEM from
biological replicates (n = 3). *p < 0.05, ***p < 0.005, ****p < 0.001.
1304 Chemistry & Biology 22, 1301–1312, October 22, 2015 ª2015 Eobserve the additive effect of XBP1s and ATF6 activation (B/A
N-glycoforms shift and reduced secretion) when XBP1s and
ATF6 are activated simultaneously.
Quantitation of the N-glycoform A/B ratio in XBP1s and
vehicle-treated samples shows a highly significant, 700% in-
crease in the relative intensity of N-glycoforms A upon XBP1s
activation relative to vehicle treatment (Figure 1F). PNGase F
digestion of CD2 secreted from XBP1s-activated and untreated
cells confirms that the shift in N-glycoform bands is attributable
entirely to altered N-glycosylation, as opposed to other possible
post-translational modifications (Figure 1G).
As a control, we analyzedCD2 in themedia and lysates of tran-
siently transfected HEK293DYG cells (Shoulders et al., 2013b). In
HEK293DYG cells, TMP treatment stabilizes DHFR.YFP and Dox
treatment induces eGFP. Analysis of CD2 in the media and ly-
sates of HEK293DYG cells shows no change in the extent of
secretion or the N-glycoforms A/B ratio upon Dox and/or TMP
treatment (Figures S1B and S1C). Thus, the results we observe
in HEK293DAX cells are attributable entirely to UPR transcription
factor activation, not to any possible off-target effects of the
small molecules employed.
In summary, XBP1s activation increases the levels of partic-
ular secreted CD2 N-glycoforms, while ATF6 activation has no
apparent effect on the N-glycoforms but does reduce the extent
of CD2 secretion. Because we were specifically interested in
effects of the UPR on the molecular architecture of the mature
N-glycome, we focused exclusively on CD2 produced from
XBP1s-activated cells for further studies.
N-Glycoform Maturation Effects Mediated by XBP1s
Activation Are Not Attributable to Altered Degradation
or Secretion
The XBP1s-mediated shift in the N-glycoform population of
mature, secreted CD2 could be caused by altered biosynthesis
of the mature N-glycan in the Golgi. A more trivial explanation
is that, under XBP1s-activated conditions, a particular CD2
N-glycoform is either degraded or secreted at a rate different
to that in untreated cells. To test the latter hypothesis, we exam-
ined CD2’s secretion and degradation rates in untreated and
XBP1s-activated HEK293DAX-CD2 cells using [35S] metabolic la-
beling (Figure 2A). Relative to untreated cells, we found that
XBP1s activation has no effect on the extent of CD2 degradation
(Figure 2B). CD2 is indeed partially degraded by the proteasome,lsevier Ltd All rights reserved
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Figure 3. Glycosidase Digestions to Characterize N-Glycans on
Secreted CD2
(A) Schematic displaying cleavage patterns of N-glycans by endo- and exo-
glycosidases. Color symbols are: purple diamond, N-acetylneuraminic acid;
blue square, N-acetylglucosamine; green circle, mannose; red triangle,
fucose.
(B–D) Immunoblots of CD2 secreted from either untreated or XBP1s-activated
HEK293DAX-CD2 cells as in Figure 1E and digested with the indicated glycosi-
dases. Endo-H cleaves both N-glycoforms A and B indicated by the black and
gray arrowheads, yielding a mono-GlcNAcylated product (B). Endo-F3 does
not significantly cleave either N-glycoforms band (C). Double digestion by the
a1–2,3- and a1–6-mannosidases reduces only the molecular weight of
N-glycoforms B (D).as shown by lactacystin-mediated proteasomal inhibition, but to
a very similar overall extent under both sets of conditions. XBP1s
activation may very modestly decrease the net secretion rate of
CD2 over the course of 8 hrs (p = 0.03), but lactacystin treatment
completely restores secretion to the levels of untreated cellsChemistry & Biology 22, 1301–1(Figure 2C). Most importantly, at any time point in the pulse-
chase experiment, and with or without proteasome inhibition,
we observe the identical shift in the CD2 N-glycoforms ratio
upon XBP1s activation (Figure 2D). These results demonstrate
that the XBP1s-mediated effects on the architecture of the
CD2 N-glycan cannot be attributed to altered CD2 secretion or
degradation upon XBP1s activation.
XBP1s Activation Primarily Favors the Synthesis of
Hybrid CD2 N-Glycans
To better understand how XBP1s activation alters N-glycan
maturation, we next employed selective endo- and exo-
glycosidase digestions to structurally classify the N-glycoforms
A and B produced from both untreated and XBP1s-activated
HEK293DAX-CD2 cells. As illustrated in Figure 3A, Endo-H cleaves
both high-mannose and hybrid N-glycans, Endo-F3 cleaves only
complex N-glycans, and the combination of a1–2,3-mannosi-
dase and a1–6-mannosidase cleaves only high-mannose N-gly-
cans (Jacob and Scudder, 1994). We found that Endo-H digests
both CD2 N-glycoform bands A and B (at the sensitivity of an
immunoblot), regardless of XBP1s activation (Figure 3B, black
and gray arrowheads), suggesting that the majority of the CD2
N-glycans present are high-mannose or hybrid. Consistent
with this observation, Endo-F3 is unable to digest either CD2
N-glycoform band to an observable extent (Figure 3C). The com-
bination of a1–2,3-mannosidase and a1–6-mannosidase, how-
ever, clearly reduces the molecular weight of N-glycoforms B
(gray arrowhead), with no effect on N-glycoforms A (Figure 3D,
black arrowhead). These observations suggest that XBP1s acti-
vation primarily enhances the biosynthesis of hybrid N-glycans
on CD2.
Small Molecule-Mediated Inhibition of Mannosidases to
Elucidate XBP1s-Mediated Effects on N-Glycan
Biosynthesis
Following the transfer of the original 14-member, dolichol-linked
N-glycan onto nascent ER client proteins, subsequent removal
of the terminal glucose residues by the ER a-glucosidases I
and II allows entry to the calnexin and/or calreticulin chaperone
folding cycles (Caramelo and Parodi, 2008; Hammond et al.,
1994). After folding, additional glucose and mannose residues
are removed to yield high-mannose N-glycans that are then
further digested by the Golgi a1–2-mannosidases (Herscovics,
1999). Subsequent to these mannosidase digestions, which
yield various additional forms of high-mannose N-glycans, the
N-glycan enters downstream processing into mature hybrid
and complex N-glycans.
Our data from enzyme digestions indicate that the CD2 N-gly-
coforms band A, whose synthesis is strongly enhanced by
XBP1s activation, is primarily hybrid. Therefore, we expected
that inhibiting the catalytic activity of mannosidase I enzymes us-
ing kifunensine would eliminate the effects of XBP1s activation
by preventing the production of mature high-mannose and
hybrid N-glycans (Elbein et al., 1990). Indeed, we find that treat-
ment with kifunensine results in observation of only a single
N-glycoforms band for secreted CD2 (Figure 4A). Although this
new band appears at a similar molecular weight to N-glycoforms
band A in untreated cells, it is molecularly distinct. Unlike N-gly-
coforms band A (see Figure 3D), the single new band generated312, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1305
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Figure 4. Effects of XBP1s Activation upon Inhibition of Mannosidases
Immunoblots are of CD2 secreted from untreated or XBP1s-activated HEK293DAX-CD2 cells as in Figure 1E.
(A) Preventing formation of both hybrid and complex N-glycans by inhibitingmannosidases with kifunensine (kif) eliminates the effects of XBP1s activation onCD2
N-glycan maturation.
(B) Double digestion by the a1–2,3 -and a1–6-mannosidases reduces the molecular weight of secreted CD2 from (A), confirming that it is a high-mannose
N-glycoform.
(C) Preventing formation of complex N-glycans by inhibiting a-mannosidase II with swainsonine (swa) has no observable impact on the effects of XBP1s activation
on CD2 N-glycan biosynthesis.
(D) Double digestion by the a1–2,3- and a1–6-mannosidases only influences the molecular weight of N-glycoforms band B from non-XBP1s-activated
HEK293DAX-CD2 cells treated with swainsonine in (C).
See also Figure S2.by kifunensine treatment is sensitive to digestion by a1–2,3-
mannosidase and a1–6-mannosidase, as determined by the
small but highly reproducible shift observable by immunoblotting
that is expected for this digestion of a high-mannose N-glyco-
form (Figure 4B). Thus, these data show that the effects of
XBP1s activation on N-glycan biosynthesis lie either at or down-
stream of the ER and Golgi mannosidase I enzymes.
Swainsonine inhibits Golgi a-mannosidase II (Tulsiani et al.,
1982), which catalyzes a required step for complex N-glycan
biosynthesis. Consistent with our enzyme digestions (Figure 3),
swainsonine treatment has no observable impact on the N-gly-
coforms shift we detect upon XBP1s activation by immunoblot-
ting (Figures 4C and 4D), suggesting once again that XBP1s is
primarily enhancing the production of hybrid N-glycans on
secreted CD2. We confirmed that Golgi a-mannosidase II is in-
hibited at the 10 mg/ml swainsonine concentration employed
by demonstrating that this treatment prevents the formation of
complex N-glycans on erythropoietin (Figure S2).1306 Chemistry & Biology 22, 1301–1312, October 22, 2015 ª2015 EGlycomic Analysis of Purified CD2 by MALDI-TOF
MS/MS
The data from our glycosidase digestion and inhibition studies
suggest that XBP1s activation primarily increases hybrid
N-glycan biosynthesis on CD2, at least at the resolution of a
gel-based analysis. To obtain a molecular-level, more quantita-
tive view of the effects of XBP1s on N-glycan maturation, we
performed structural analysis on the N-glycans released from
purified CD2 using MALDI-TOF tandem mass spectrometry
(MS/MS) (Ceroni et al., 2008; Jang-Lee et al., 2006). We first opti-
mized a protocol to obtain hundreds of mg quantities of highly pu-
rified secreted CD2 from both untreated and XBP1s-activated
HEK293DAX-CD2 cells (see Figure S3A). For the untreated sample,
we separately extracted N-glycoforms bands A and B for
MALDI-TOF MS/MS analysis. The N-glycoforms band B in the
untreated sample (Figure 5A) is relatively homogeneous, with
95% of the N-glycans being high-mannose and the 5%
hybrid likely deriving from cross-contamination by the higherlsevier Ltd All rights reserved
Figure 5. Mass Spectrometry-Based Glycomic Analyses Reveal the Molecular Structures of CD2 N-Glycans upon XBP1s Activation
MALDI-TOF mass spectra of permethylated N-glycans released by PNGase F digestion of CD2 purified from the media of untreated or XBP1s-activated
HEK293DAX-CD2 cells. In untreated cells, N-glycoforms bands A (A) and B (B) were analyzed separately. In XBP1s-activated cells, the bands were analyzed
together (C).
(legend continued on next page)
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Table 1. Summary of MALDI-TOF MS/MS Glycomic Analyses
of CD2
Vehicle (%) XBP1s (%)
N-Glycan Classification Type
Complex 5 16
Hybrid 35 74
High-mannose 61 11
N-Glycan Terminal Epitopea
LacdiNAc 29 19
Fuc-LacdiNAc 47 39
LacNAc 10 15
LeX/A (Lewis X/A)b 4 10
LeY/B (Lewis Y/A)b 7 11
S-LacNAcc 4 6
aLacNAc, N-acetyllactosamine; LacdiNAc, N,N0-diacetyllactosamine;
Fuc-LacdiNAc, fucosylated LacdiNAc; S-LacNAc, sialylated LacNAc.
bLewis glycan epitope types.
cSialylated LacdiNAc not detected.molecular weight band A, owing to imperfect separation of the
bands on SDS-PAGE. The N-glycoforms band A in the untreated
sample is 78% hybrid and 9% complex (Figure 5B). After
normalizing to the relative intensities of N-glycoforms bands A
and B in untreated samples (Figure 1F), theseMS results indicate
that, in untreated cells, approximately 61% of the CD2 produced
displays high-mannose N-glycans, 35% hybrid, and 5%
complex (Table 1).
XBP1s activation almost entirely eliminates the lower molecu-
lar weight N-glycoforms band B, rendering separate extraction
and glycomic analysis of N-glycoforms band B unfeasible.
Therefore, for analysis of N-glycans on CD2 secreted from
XBP1s-activated cells, we simply extracted the entire CD2 re-
gion from an SDS-PAGE gel (see Figure S3A). Strikingly,
MALDI-TOFMS/MS analysis shows that11% of the N-glycans
on CD2 produced from XBP1s-activated cells are high-
mannose, 74% are hybrid, and16% are complex (Figure 5C;
Table 1). Normalizing to the relative intensities of bands A and B
for the vehicle-treated sample, these results confirm our predic-
tion from enzyme digestions and small-molecule inhibition ex-
periments that XBP1s activation strongly favors the biosynthesis
of hybrid N-glycans on CD2.
qPCR analyses show that transcripts for MAN1A1 and
MGAT1 (which encodes GNT-I) are upregulated by XBP1s acti-
vation (Figure S3B). These two proteins are responsible for(A) N-Glycoforms band B for CD2 secreted from untreated cells is homogeneous
(B) N-Glycoforms band A for CD2 secreted from untreated cells is primarily hybr
(C) For CD2 from XBP1s-activated cells, N-glycoforms bands A and B were analy
XBP1s-activated sample than in the vehicle-treated sample (e.g., m/z 1,999, 2,0
2,418, 2,459, 2,592, 2,605, 2,633, 2,646, 2,820, and 2,837 for complex structur
intensities of bands A and B from vehicle-treated cells. Differences are also noted i
are presented in Table 1.
Color symbols are: yellow square, N-acetylgalactosamine; blue square, N-acetylg
N-acetylneuraminic acid; red triangle, fucose. All molecular ions are [M + Na]
knowledge. Structures that show sugars outside a bracket have not been unequ
minor, minor, and major abundances, respectively.
See also Figure S3.
1308 Chemistry & Biology 22, 1301–1312, October 22, 2015 ª2015 Etrimming mannose residues and transferring the first N-acetyl-
glucosamine onto an N-glycan, two critical biosynthetic steps
for formation of hybrid N-glycans, and thus could be involved
in the observed XBP1s-mediated shift toward hybrid N-gly-
cans. The higher sensitivity of the MALDI-TOF MS/MS analysis
relative to immunoblotting allows us to also observe the >3-fold
enhancement in the synthesis of complex N-glycans upon
XBP1s activation, which could be mediated in part by
MGAT2 (which encodes GNT-II), another protein whose tran-
script levels are upregulated by XBP1s (see qPCR data in Fig-
ure S3B). MGAT2 catalyzes an early step in the biosynthesis of
complex N-glycans.
We note that a number of N-glycoforms are observed upon
XBP1s activation that are simply not present on CD2 secreted
from untreated cells (Figure 5). In addition, our MALDI-TOF MS/
MS glycomic analyses provide molecular details regarding the
terminal structures of the hybrid and complex N-glycans pro-
duced in untreated and XBP1s-activated cells. Of particular
note, XBP1s activation shifts the population of terminal
N-glycoform epitopes observed. Under untreated conditions,
76% of the N-glycoforms display either LacdiNAc or Fuc-
LacdiNAc terminal epitopes. Upon XBP1s activation this popu-
lation drops to 58%, with a corresponding modest increase in
LacNAc, LeX/A, LeY/B, and sialylated (S-LacNAc) terminal epi-
topes (Table 1).XBP1s-Mediated Effects on N-Glycan Maturation Are
Generalizable beyond CD2 and HEK293 Cells
We wondered whether the effects on N-glycan biosynthesis
we observe are CD2-specific, or are present more broadly for
other N-glycoproteins. To explore this possibility, we created
a construct for the expression and analysis of the collagen-
a1(I) C-propeptide domain (Shoulders and Raines, 2009). We
selected the collagen-a1(I) C-propeptide to study because, like
CD2, this35-kDa secreted protein has a single N-glycosylation
sequon and displays two N-glycoforms bands separable by
SDS-PAGE upon secretion from HEK293DAX cells. We analyzed
hemagglutinin (HA) epitope-tagged collagen-a1(I) C-propeptide
samples secreted from untreated and XBP1s-activated samples
by immunoblotting. We observe that XBP1s activation once
again increases the population of a higher molecular weight
N-glycoforms band (Figures 6A and S4A), without altering the
extent of protein secretion and with minimal effects on intracel-
lular levels of the collagen-a1(I) C-propeptide (Figure 6B). Inter-
estingly, ATF6 activation again decreases the net secretion of
the protein with no apparent effects on N-glycosylation, whileand high-mannose.
id.
zed together. Hybrid and complex N-glycans are much more prominent in the
40, 2,173, 2,214, 2,347, and 2,360 for hybrid structures and m/z 2,211, 2,285,
es), a difference whose magnitude is illustrated by normalizing to the relative
n the terminal N-glycan epitopes relative to untreated cells. These quantitations
lucosamine; yellow circle, galactose; green circle, mannose; purple diamond,
+. Putative structures are based on composition, MS/MS, and biosynthetic
ivocally defined. Letters ‘‘vm’’, ‘‘m’’, and ‘‘M’’ in bold characters suggest very
lsevier Ltd All rights reserved
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Figure 6. XBP1s Activation Modulates the Molecular Architecture of
Mature N-Glycans on the Collagen-a1(I) C-Propeptide and in Saos-2
Cells
(A) Representative immunoblot of the collagen-a1(I) C-propeptide in media
collected from HEK293DAX cells stably expressing the protein after 48 hr of
stress-independent XBP1s and/or ATF6 activation (Dox at 1 mg/ml and/or TMP
at 10 mM). Two N-glycoforms bands A and B are observed, as indicated by the
arrowheads. XBP1s activation enhances levels of the top band. Control media
were harvested from parent HEK293DAX cells.
(B) Representative immunoblot of lysates corresponding to themedia samples
in (A).
(C) Immunoblot showing PNGase F digestion of collagen-a1(I) C-propeptide
samples secreted from untreated and XBP1s-activated HEK293DAX cells as in
(A). Two N-glycoforms bands A and B are observed, as indicated by the black
and gray arrowheads, respectively.
(D) Immunoblot of CD2 secreted over 48 hr from transiently transfected Saos-2
cells co-transduced with either a GFP-encoding or an XBP1s-encoding adeno-
virus. Samples for analysis were obtained via a FLAG-M2-mediated immuno-
precipitation of CD2 from the media. Two N-glycoforms bands A and B are
observed, as indicated by the arrowheads. XBP1s activation enhances levels of
the top band. Control mediawere harvested fromGFP-transfected Saos-2 cells.
See also Figure S4.the combination of XBP1s and ATF6 activation displays an addi-
tive effect similar to the consequences for CD2 (Figure 6A).
PNGase F digestion confirms that the XBP1s-induced shift is
caused by an alteration in the N-glycans, as the banding patternsChemistry & Biology 22, 1301–1for collagen-a1(I) C-propeptides secreted fromboth XBP1s-acti-
vated and untreated cells are identical upon PNGase F digestion
(Figure 6C).
We next queried whether the effects of XBP1s activity on
N-glycan maturation are limited only to HEK293 cells. CD2
secreted from transiently transfected Saos-2 osteosarcoma
cells is observed as a smear of N-glycoforms concentrated in
two bands, as confirmed by PNGase F digestion (Figure S4B).
We transiently transfected CD2 into Saos-2 osteosarcoma cells,
transduced the cells with either a GFP or an XBP1s-encoding
adenovirus, and examined the N-glycosylation pattern on
secreted CD2 under both conditions. We observe a strong
enhancement of higher molecular weight N-glycoforms in cells
where XBP1s is expressed (Figure 6D). Together, these data
indicate that the striking impacts of XBP1s activation on
N-glycanmaturation are restricted neither just to the CD2 protein
nor just to HEK293 cells.
DISCUSSION
Our results demonstrate the capacity of XBP1s-mediated re-
modeling of the ER proteostasis environment to enhance the
biosynthesis of particular hybrid and complex N-glycans.
Although it is not yet possible to conclusively attribute the
observed alterations in N-glycan maturation to specific enzymes
upregulated by XBP1s in Figure 1A, roles for the upregulation of
GNT-I and MAN1A1 in the enhanced synthesis of hybrid N-gly-
cans and the upregulation of GNT-II in the enhanced synthesis
of complex N-glycans are plausible. We speculate that similar
XBP1s-induced effects may apply more broadly across the
endogenous N-glycoproteome. In ongoing work, we are per-
forming N-glycoproteome-wide studies on endogenous proteins
in the context of small molecule-mediated UPR activation to
explore this possibility.
Considering the classical role of the UPR in resolving protein
misfolding stress, there is the possibility that XBP1s-mediated
changes in N-glycosylation patterns assist ER protein folding
either indirectly by orchestrating interactions with ER proteo-
stasis network components or directly by altering folding
biophysics. Bearing in mind that the IRE1-XBP1s axis is the
only arm of the UPR conserved across all eukaryotes (Walter
and Ron, 2011), it is alternatively possible that XBP1s simply
plays a critical role in regulating all aspects of ER client produc-
tion. The effects observed need not be linked directly to resolving
proteinmisfolding stress. In such a scenario, regulating N-glycan
maturation is a previously unappreciated, yet nonetheless crit-
ical role of XBP1s.
There are diverse potential biological implications of XBP1s-
mediated regulation of the molecular architecture of mature
N-glycans. For example, specific N-glycan structures have roles
in processes including protein sorting to microvesicles (Batista
et al., 2011) and cell-cell recognition (Sharon, 2007) that would
be influenced by altered N-glycan maturation. In addition, a
number of secreted proteins displaying high-mannose N-glyco-
forms after Golgi processing are known (de Leoz et al., 2011;
Satoh et al., 2007), so a specific shift away from high-mannose
N-glycans upon XBP1s activation could influence protein recog-
nition and uptake via the mannose receptor (East and Isacke,
2002). Altered N-glycosylation upon XBP1s activation could312, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1309
also potentially play a role in transcellular communication of ER
stress (Taylor and Dillin, 2013), an XBP1s-dependent and impor-
tant biological process for which the relevant signaling molecule
remains to be identified.
Of particular interest is the correlation between unusual N-gly-
coform populations in many cancers (Fry et al., 2011; Ha¨usel-
mann and Borsig, 2014; Stowell et al., 2015) and constitutive
activation of the IRE1-XBP1s UPR axis in certain malignancies
(Bagratuni et al., 2010; Carrasco et al., 2007; Fujimoto et al.,
2003). There is the possibility that XBP1s activity mechanistically
links particular neoplastic N-glycosylation patterns to chronic ER
protein misfolding stress in cancer. An XBP1s-induced shift to-
ward hybrid and especially certain complex N-glycans could
enhance tumor invasiveness (Stowell et al., 2015). Our data in
Table 1 also suggest that XBP1s activation may increase sialyla-
tion. To date, three mechanisms have been proposed to induce
hypersialylation in cancer (Bu¨ll et al., 2014); XBP1s activation
may represent a fourth mechanism.
Aside from the intriguing biological implications of our find-
ings, we also note that XBP1s activation has previously been em-
ployed to increase the yield of recombinant antibodies and other
proteins (Tigges and Fussenegger, 2006). Our findings suggest
that controlling XBP1s provides a valuable mechanism to modu-
late N-glycan biosynthesis on recombinant N-glycoproteins,
particularly in caseswhere undesirable high-mannose N-glycans
are abundantly produced.
SIGNIFICANCE
The cellular mechanisms that dynamically regulate the
N-glycome remain poorly understood. Here, we leverage
chemical biology tools for stress-independent, small mole-
cule-mediated control of the UPR to discover that the UPR
can regulate the molecular architecture of mature N-linked
glycans via XBP1s-mediated remodeling of N-glycan bio-
synthesis pathways. Specifically, we show that XBP1s acti-
vation strongly enhances the synthesis of particular hybrid
and complex N-glycans on model secreted proteins.
Detailed glycomic analyses show that the identities of termi-
nal N-glycan epitopes are also influenced by XBP1s activa-
tion. These effects cannot be attributed to altered secretion
or degradation of particular N-glycoforms, indicating a
genuine alteration of N-glycan maturation. Our results are
significant because they provide amechanistic link between
intracellular stress responses classically involved in main-
taining proteostasis and the molecular architecture of the
extracellular N-glycome. There are numerous plausible bio-
logical consequences of this freshly drawn connection.
In particular, it is well-established that many malignant
cells display both unusual N-glycosylation patterns and
constitutive XBP1s activation. There may be a causative
relationship between these two observations, a possibility
we are currently exploring. Also noteworthy, the trafficking
of many proteins is influenced by their N-glycan structures,
as are the strengths of interactions between N-glycopro-
teins and various lectins or cell surface proteins. Via these
pathways, XBP1s-mediated effects on N-glycan architec-
tures may play a functional role in processes ranging from
cancer metastasis to auto-immunity. Furthermore, transcel-1310 Chemistry & Biology 22, 1301–1312, October 22, 2015 ª2015 Elular communication of stress signals plays an important
role in organism survival in the face of stress, yet the
signaling molecule has remained elusive. XBP1s-altered
N-glycosylation patterns may play a role. Finally, improved
methods are needed to optimize N-glycan architectures on
recombinant proteins produced for biotechnology applica-
tions. Small molecule-mediated, stress-independent con-
trol of XBP1s signaling could prove useful for such a
purpose.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, and Transfections
HEK293 cells were cultured in DMEM supplemented with glutamine, penicillin/
streptomycin, 10% fetal bovine serum (FBS), and appropriate selection agents
as previously described (Shoulders et al., 2013b). A stable HEK293DAX-CD2 cell
line constitutively expressing the CD2 adhesion domain from R. norvegicus,
whose primary amino acid sequence is shown in the Supplemental Experi-
mental Procedures, was created by transduction of HEK293DAX cells with
CD2-encoding lentivirus (Campeau et al., 2009) and maintained in 1.2 mg/ml
puromycin after single colony selection. A stable HEK293DAX cell line express-
ing the collagen-a1(I) C-propeptide was created by calcium phosphate-medi-
ated co-transfection of the appropriate vector (vide infra) with a puromycin
linear marker (ClonTech) and selection in 1.2 mg/ml puromycin. Saos-2 cells
were cultured in complete DMEM supplemented with 15% heat-inactivated
FBS. Transient transfections of eGFP-N3 or CD2.pFLAG-CMV3 were per-
formed using polyethylenimine or X-tremeGENE 9 (Roche).
eGFP-N3 and CD2.pFLAG-CMV3 were generous gifts from Professor J.W.
Kelly (Scripps Research Institute). For lentivirus production, the gene encoding
CD2 was transferred to pENTR1A using the BamHI and NotI sites and then
shuttled into pLenti.CMV.Puro DEST (Campeau et al., 2009) using LR clonase
II-mediated recombination. The C-propeptide domain of COL1A1 (residues
1,218–1,464) was PCR-amplified from a COL1A1-encoding vector and in-
serted into the pcDNA3.1 vector downstream of a 50-preprotrypsin signal
sequence followed by an HA epitope tag.
Immunoblotting and SDS-PAGE
Proteins were separated by SDS-PAGE using 12% Bis-Tris gels. Immunoblot-
ting was performed as previously described (Shoulders et al., 2013b) and
analyzed using a Li-Cor Biosciences Odyssey Imager. Antibodies employed
are listed in the Supplemental Experimental Procedures.
Quantitative RT-PCR
The relative mRNA expression levels of target genes were measured using
quantitative RT-PCR (see the Supplemental Experimental Procedures for de-
tails and Table S2 for a list of primers used).
[35S] Metabolic Labeling Experiments
HEK293DAX-CD2 cells seeded on poly-D-lysine-coated plates were treated with
Dox at 1 mg/ml to activate XBP1s for 24 hr. Cells were then starved for 1 hr in
DMEM + 10% FBS lacking Cys and Met. Cells were metabolically labeled in
pulse medium containing [35S]-Cys/Met (MP Biomedicals, 0.1 mCi/ml final
concentration) for 20 min, then incubated in pre-warmed chase media for
the indicated times. Lactacystin (10 mM) was added as indicated at the begin-
ning of the chase period. Medium was collected and cells were lysed in a 1%
Triton X-100 buffer. CD2 was immunopurified using M2 anti-FLAG agarose
beads (Sigma; A2220) and washed with radio-immunoprecipitation assay
buffer. Immunoisolates were eluted by boiling in 63 Laemmli buffer and sepa-
rated by SDS-PAGE. The gels were then dried, exposed to phosphorimager
plates (GE Healthcare), and imaged with a Typhoon imager. Band intensities
were quantified in ImageQuant TL.
Enzyme Digestions
PNGase F, Endo-H, Endo-F3, a1–2,3-mannosidase, and a1–6-mannosidase
were obtained from NEB. Digestions were performed according to the manu-
facturer’s protocols.lsevier Ltd All rights reserved
MALDI-TOF MS/MS Glycomic Analyses
CD2 was purified upon secretion from untreated and XBP1s-activated
HEK293DAX-CD2 cells and purified CD2 SDS-gel bands were processed for
N-glycan analysis as described in the Supplemental Experimental Procedures.
MS and MS/MS data were acquired using a 4800 MALDI-TOF/TOF (Applied
Biosystems) mass spectrometer. For MS/MS, the collision energy was set to
1 kV. Ar was used as the collision gas. The 4700 calibration standard kit,
Calmix (Applied Biosystems), was used as the external calibrant for the MS
mode of both instruments. Human [Glu1] fibrinopeptide B (Sigma) was used
as an external calibrant for the MS/MS mode of the MALDI-TOF/TOF instru-
ment. MS and MS/MS data were processed using Data Explorer 4.9 (Applied
Biosystems) following the detailed protocol presented in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information including Supplemental Experimental Procedures,
two tables, and four figures can be found with this article online at http://dx.
doi.org/10.1016/j.chembiol.2015.09.006.
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